Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-10-2000 | Meeting abstract

A trial of duplicating film for mammography

Author: GR Clough

Published in: Breast Cancer Research | Special Issue 2/2000

Login to get access

Excerpt

When reporting mammograms it is essential that comparisons, where possible, are made with the patient's previous examinations. NHS breast screening units do not routinely release original mammograms to other sources for reporting comparisons. The quality of duplicate mammograms varies enormously. One of the factors associated with this variation is the type of duplicating film used. A trial of five leading film manufacturers duplicating film (Agfa, Fuji, Kodak, Konica and Sterling) was undertaken. Sensitometry tests were carried out and duplicates of Tor Mas, Tor Mam and mammograms of different breast types were produced and scored. The results from the Tor Mam test were inconclusive, while the scores from the Tor Mas and mammograms showed marked differences between the makes of duplicating film. Characteristic curves for all duplicates and the original film were drawn. The gamma of each film was calculated and ranged from 3.25 to 5.07. A one-sample t-test was carried out on the data from the characteristic curves to look for a statistical difference between the duplicate films and the original. P values ranged from 0.27 to 0.0005 with P < 0.01 being statistically significant. Kodak duplicating film performed well in all tests, Fuji and Sterling scored poorly. …
Metadata
Title
A trial of duplicating film for mammography
Author
GR Clough
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr240

Other articles of this Special Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine